THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Kamil Paruch et al.

Serial No.: 10/666,424

Filed: 09/19/2003

For: **NOVEL IMIDAZOPYRAZINES AS CYCLIN**

DEPENDENT KINASE INHIBITORS

Group Art Unit: To Be Assigned

Examiner: To Be Assigned

Attorney Docket No.: OC01626K

INFORMATION DISCLOSURE STATEMENT AND SUBMISSION OF INTERNATIONAL SEARCH REPORT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:			
PTO-1449 application.	Form be Copy(ie	consides) of	it is requested that the documents listed on the accompanying dered and made of record in the above-identified patent these references are attached were filed in related filed , respectively.
(b)	No fee	is belie	eved due because:
			nformation Disclosure Statement is being filed within three (3) s of the filing date of the application.
			formation Disclosure Statement is being concurrently filed with ove-identified application.
			formation Disclosure Statement is being concurrently filed with uest for Continued Examination (RCE).
	\boxtimes		nformation Disclosure Statement is being filed prior to the g of a first Office Action on the merits.
(c)		This Information Disclosure Statement is being filed before the mailidate of any final action, notice of allowance or an action that otherwicloses prosecution; and	
			Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
			No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or
			The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.


Serial No. <u>10/666,424</u> March 26, 2004 Page 2 of 2

*** 4 × 2

	(d)		This Information Disclosure Statement is being filed on or before the payment of the issue fee; and				
				Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or			
				No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and			
				The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.			
The Commissioner is hereby authorized to charge any additional fees we required for this Information Disclosure Statement, or credit any over Deposit Account No. 19-0365, Patent Case No. OC01626K.							
				Respectfully submitted, SCHERING-PLOUGH CORPORATION			
SCHER Patent 2000 C Kenilw	ING-PLO Depart Sallopinorth, N	h 26, 20 OUGH Co tment, K ng Hill Ro J 07033 : (908)	 ORPORA (-6-1, 19 oad 3-0530	90 Reg. No.: 34,634 Attorney of Record Telephone No.: (908) 298-5068			

Attorney Docket No.: OC01626K

PTO/SB/92 (08-03) (Modified)



Title: "Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors"

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on —	03/26/2004	
	Date	•
		De
		Signature
		Palaiyur S. Kalyanaraman, Reg. No. 34,634
		Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents enclosed:

Certificate of Mailing - 1pg.

Information Disclosure Statement - 2pgs.

Copy of International Search Report - 5pgs.

PTO-1449 Form - 2pgs. in duplicate

References (6)

Post Card

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.